AMGEN TO PRESENT AT THE TD COWEN 4TH ANNUAL ONCOLOGY INNOVATION SUMMIT

On May 26, 2023 Amgen (NASDAQ: AMGN) reported that it will present at the TD Cowen 4th Annual Oncology Innovation Summit at 11:00 a.m. ET on Wednesday, May 31, 2023. David M. Reese, M.D., executive vice president of Research and Development at Amgen will present at the conference (Press release, Amgen, MAY 26, 2023, View Source [SID1234632134]). The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast, as with other selected presentations regarding developments in Amgen’s business given by management at certain investor and medical conferences, can be found on Amgen’s website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen’s Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.

PharmaMar announces the abstracts that will be presented at the ASCO 2023 congress

On May 26, 2023 PharmaMar (MSE:PHM) has reported that it will present, together with its partners, seven new abstracts from various clinical studies with Zepzelca (lurbinectedin) and Yondelis (trabectedin) at the annual meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) (ASCO, American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper)), which will be held from June 2 to 6, 2023 virtually and in person in Chicago, United States (Press release, PharmaMar, MAY 26, 2023, View Source [SID1234632088]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Among the studies that will be presented during the congress, two oral presentations with two PharmaMar compounds stand out. With the abstract titled: " Efficacy of combination lurbinectedin (LURBI) + doxorubicin (DOX) from the phase 1B soft-tissue sarcoma (STS) lead-in to a randomized phase 2 trial in leiomyosarcoma (LMS)", Dr. Gregory Cote , a medical oncologist at Massachusetts General Hospital, will present updated efficacy and tolerability data of the combination of lurbinectedin with doxorubicin, from the phase 1B introduction of soft tissue sarcoma to a phase II randomized trial in leiomyosarcoma (LMS).

For his part, Dr. Peter Reichardt, Chief Medical Officer of the HELIOS Klinikum Berlin-Buch Interdisciplinary Oncology Clinic, will present the abstract entitled: "Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc)", in which he will present data on the efficacy and safety of trabectedin plus nivolumab as second-line treatment of patients with metastatic or inoperable soft tissue sarcoma previously treated with anthracyclines. The study confirms the activity of trabectedin plus nivolumab, particularly in patients with lipo or leiomyosarcomas, suggesting a synergistic activity. Furthermore, the safety of trabectedin and nivolumab was consistent with the safety profiles of each drug separately, with no new findings relevant to the combination.

All ASCO (Free ASCO Whitepaper) abstracts are available upon request to registered participants for 180 days from May 26, 2023: View Source

Studies featured at ASCO (Free ASCO Whitepaper) 2023

PRODUCT TITLE PRIMARY AUTHOR ABSTRACT
Zepzelca (lurbinectedina) Efficacy of combination lurbinectedin (LURBI) + doxorubicin (DOX) from the phase 1B soft-tissue sarcoma (STS) lead-in to a randomized phase 2 trial in leiomyosarcoma (LMS) Gregory Cote ABSTRACT: 11507 SESSION TYPE: Oral Abstract Session S100a DATE: June 5, 2023 11:30 – 14:30 GMT-5
Zepzelca (lurbinectedina) Efficacy and safety of lurbinectedin in elderly patients with relapsed SCLC Sophie Cousin ABSTRACT: 8591 SESSION TYPE: Poster Session POSTER: 218 DATE: June 4, 2023 8:00 – 11:00 GMT-5
Zepzelca (lurbinectedina) A phase III study of lurbinectedin alone or in combination with irinotecan vs investigator’s choice (topotecan or irinotecan) in patients with relapsed small cell lung cancer (SCLC; LAGOON trial) Benjamin Besse ABSTRACT: TPS8613 SESSION TYPE: Poster Session POSTER: 233a DATE: June 4, 2023 8:00 – 11:00 GMT-5
Zepzelca (lurbinectedina) IFCT-2105 lurbiclin real-world effectiveness and treatment sequences in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) who received lurbinectedin as part of the French Early Access Program (EAP-ATU) Nicolas Girard ABSTRACT: 8584 SESSION TYPE: Poster Session POSTER: 211 DATE: June 4, 2023 8:00 – 11:00 GMT-5
Yondelis (trabectedin) Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc) Peter Reichardt ABSTRACT: 11500 SESSION TYPE: Oral Abstract Session S100a DATE: June 5, 2023 11:30 – 14:30 GMT-5
Yondelis (trabectedin) SARC037: Results of phase I study of trabectedin given as a 1-hour (h) infusion in combination with low dose irinotecan in relapsed/refractory Ewing sarcoma (ES) Patrick Grohar ABSTRACT: 11519 SESSION TYPE: Poster Discussion Session POSTER: 453 DATE: June 3, 2023 16:30 – 18:00 GMT-5
Yondelis (trabectedin) Trabectedin (T) versus adriamycin plus dacarbazine (A-DA) in advanced solitary fibrous tumor (SFT): Results from a phase II randomised clinical study (STRADA) Silvia Stacchiotti ABSTRACT: 11571 SESSION TYPE: Poster Session POSTER: 505 DATE: June, 2023 13:15 – 16:15 GMT-5

Chugai Obtains Approval for FoundationOne Liquid CDx Cancer Genomic Profile to Be Used as a Companion Diagnostic for Novartis’ MET Inhibitor, Capmatinib, Which Is Approved for MET Exon 14 Skipping Mutation-Positive Advanced and/or Recurrent Unresectable Non-Small Cell Lung Cancer

On May 26, 2023 Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) reported that it has obtained approval from the Ministry of Health, Labour and Welfare (MHLW) on May 25, 2023, for FoundationOneLiquid CDx Cancer Genomic Profile to be used as a companion diagnostic for an anti-cancer agent/MET inhibitor, Tabrecta (generic name: capmatinib hydrochloride hydrate) of Novartis Pharma K.K. (Novartis), which is approved for the treatment of MET exon 14 skipping mutation-positive advanced and/or recurrent unresectable non-small cell lung cancer (NSCLC) (Press release, Chugai, MAY 26, 2023, View Source;category= [SID1234632087]). With this approval, patients with advanced NSCLC who may be eligible for treatment with capmatinib can be identified through both tissue-based and liquid-based comprehensive genomic profiling (CGP) tests.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are pleased that FoundationOne Liquid CDx Cancer Genomic Profile was approved as a companion diagnostic for capmatinib for advanced and/or recurrent unresectable NCSLC, in addition to the currently approved tissue-based FoundationOne CDx Cancer Genomic Profile," said Chugai’s President and CEO, Dr. Osamu Okuda. "Obtaining tissue samples can be a challenge for patients with NSCLC. Therefore, blood-based testing is an important option when considering treatment options for patient care. We are committed to advancing personalized healthcare by continuing to collaborate with many biopharma partners."

With this approval FoundationOne Liquid CDx Cancer Genomic Profile can be used as a companion diagnostic for capmatinib in advanced and/or recurrent unresectable NSCLC. It identifies patients eligible for the treatment by detecting MET exon 14 skipping gene alterations. The efficacy and safety of capmatinib in patients with advanced and/or metastatic NSCLC patients with MET exon 14 skipping alterations were investigated in the Phase II GEOMETRY mono-1 study conducted by Novartis. Novartis received approval from the MHLW in June 2020 for commercialization.

As a leading company in the field of oncology, Chugai is committed to realizing advanced personalized healthcare in oncology and contributing to patients through the expansion of CGP.

Approval information The underlined part has been newly added.
Intended uses or indications

The Product is used for comprehensive genomic profiling of blood samples in patients with solid tumors.
The Product is used for detecting gene mutations and other alterations to support the assessment of drug indications listed in the table below.
Alterations Cancer type Relevant drugs
Activated EGFR alterations
Non-small cell lung cancer (NSCLC) afatinib dimaleate, erlotinib hydrochloride, gefitinib, osimertinib mesilate
EGFR exon 20 T790M alterations osimertinib mesilate
ALK fusion genes alectinib hydrochloride, crizotinib, ceritinib
ROS1 fusion genes entrectinib
MET exon 14 skipping alterations capmatinib hydrochloride hydrate
NTRK1/2/3 fusion gene Solid tumors entrectinib
BRCA1/2 alterations Prostate cancer olaparib
About FoundationOne Liquid CDx Cancer Genomic Profile

Developed by Foundation Medicine Inc. based in Cambridge, USA, FoundationOne Liquid CDx Cancer Genomic Profile is a next-generation sequencing-based in vitro diagnostic device using blood samples for advanced cancer patients with solid tumors. It is intended to identify genomic alterations in 324 cancer-related genes through the detection of circulating tumor DNA (ctDNA) in blood. The test is approved by the MHLW for use in cancer genome profiling to report alterations (substitutions, insertion/deletion and select gene rearrangements) for short variants in 324 genes. It is also indicated for use as a companion diagnostic to identify patients who may benefit from treatment with specific targeted therapies (listed in the Table above of Intended uses or indications). For the latest information about the product, including companion diagnostic indications, please refer to the approval information.

Trademarks used or mentioned in this release are protected by laws.

Erasca to Present Promising Preliminary HERKULES-3 Phase 1b Data at the 2023 ASCO Annual Meeting

On May 25, 2023 Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, reported preliminary Phase 1b data for ERAS-007 combinations in patients with GI malignancies from two poster presentations at the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting in Chicago, Illinois (Press release, Erasca, MAY 25, 2023, View Source [SID1234639355]). The posters will be available online at Erasca.com/science/presentations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Early clinical data from HERKULES-3 continue to reinforce the potential to combine ERAS-007 with multiple agents and its potential as a backbone therapy to treat patients with GI malignancies. Importantly, these preliminary findings support a data-driven approach to refine the focus of our initial clinical development efforts on indications holding significant promise," said Jonathan E. Lim, M.D., Erasca’s chairman, CEO, and co-founder. "Our initial evaluation of the ERAS-007 + EC combination in patients with BRAF-mutated metastatic CRC will focus on EC-naïve patients based on the preliminary activity observed in HERKULES-3. By evaluating efficacy and safety in a larger sample size of patients treated at the 100 mg BID-QW dose of ERAS-007 with EC, we believe we will be able to better assess whether the promising response rate and duration of treatment observed with the triplet can be maintained."

Poster Presentation Highlights

Abstract 3557 – Preliminary results from ERAS-007 plus encorafenib and cetuximab (EC) in patients (pts) with metastatic BRAF V600E-mutated colorectal cancer (CRC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers)

ERAS-007 in combination with encorafenib (BRAFTOVI) + cetuximab (ERBITUX) demonstrated promising preliminary clinical activity in EC-naïve patients with metastatic BRAF V600E-mutated CRC. EC is currently approved for the treatment of patients with metastatic BRAF V600E-mutated CRC, as detected by an FDA-approved test, after prior therapy; however, only approximately 20% of patients experience an objective response in the second and later line of treatment setting. Downstream ERK inhibition through ERAS-007 may prevent resistance to upstream BRAF/EGFR inhibition when combined with EC. As of the data cutoff date of March 23, 2023:

40% (2/5) response rate and 60% (3/5) disease control rate (complete response + partial response + stable disease) in EC-naïve response evaluable patients at the highest dose of ERAS-007 tested (100 mg BID-QW), with duration of exposure for both responders > 34 weeks as of the data cutoff date; across all dose levels in EC-naïve response evaluable patients, 29% (2/7) response rate and 57% (4/7) disease control rate
ERAS-007 + EC was generally well-tolerated with mostly low-grade adverse events at all combination doses tested
One dose-limiting toxicity (DLT) was reported for ERAS-007 100 mg BID-QW + EC (Grade 3 macular edema)
Pharmacokinetic (PK) exposures of ERAS-007, encorafenib, and cetuximab were comparable to monotherapy values, suggesting no clinically significant PK drug-drug interactions between the study drugs
Additional HERKULES-3 Phase 1b combination data in EC-naïve patients with BRAF-mutated CRC expected between H2 2023 and H1 2024

Abstract 3558 – Preliminary results from ERAS-007 plus palbociclib (palbo) in patients (pts) with KRAS/NRAS mutant (m) colorectal cancer (CRC) or KRASm pancreatic ductal adenocarcinoma (PDAC) in HERKULES-3 study: A phase 1b/2 study of agents targeting the mitogen-activated protein kinase (MAPK) pathway in pts with advanced gastrointestinal malignancies (GI cancers)

ERAS-007 in combination with palbociclib (IBRANCE) demonstrated a lack of clinical activity in patients with KRAS/NRAS mutant CRC and KRAS mutant PDAC. Palbociclib is indicated for the treatment of adult patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer in combination with an aromatase inhibitor as initial endocrine based therapy or with fulvestrant in patients with disease progression following endocrine therapy. Based on these data, the combination of ERAS-007 and palbociclib will not be pursued further in this patient population.

Dr. Lim continued, "Our pioneering efforts exploring the potential of targeting adjacent pathways with terminal node inhibition of the RAS/MAPK pathway (ERAS-007) and cell cycle inhibition (palbociclib) did not demonstrate clinical activity in the initial evaluation. While we will not pursue further development of this combination in this patient population, it has contributed to our understanding and characterization of ERAS-007."

The Investigator Initiated Phase II Trial at MD Anderson Cancer Center combining CB-103 and Venetoclax for the treatment of rr/r-T-ALL patients is now open for recruitment

On May 25, 2023 Cellestia Biotech reported that the Investigator Initiated Phase II Trial at MD Anderson Cancer Center combining CB-103 and Venetoclax for the treatment of relapsed-refractory T cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL /LBL) is now open for recruitment (Press release, Cellestia Biotech, MAY 25, 2023, View Source [SID1234632333]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

CB-103 is a small molecule transcriptional pan-NOTCH inhibitor with a novel mechanism of action. A Phase I clinical trial has shown promising safety and tolerability, proof of biological activity, and signs of efficacy. A new investigator- initiated trial (IIT) is starting at The University of Texas MD Anderson Cancer Center, in the departments of Pediatrics and Adult Leukemia, to combine the potential of NOTCH and BCL2 inhibition considering the biological synergies between the two pathways. CB-103, in combination with Venetoclax, will be tested for the treatment of relapsed-refractory T cell acute lymphoblastic leukemia/lymphoma (r/r T-ALL/LBL in patients 12-40 years old). Added to the ongoing anti-leukemia treatment, CB-103 administration to a r/r T-ALL patient under a compassionate use program resulted in a complete response making the patient eligible for Hematopoietic Stem Cell Transplant. The IIT trial at MD Anderson is now open for patient recruitment.